Events

Event When
Full-Year 2019 Financial Results reporting* February 6, 2020
First Quarter 2020 Financial Results reporting* April 23, 2020
Annual General Meeting of Shareholders May 13, 2020
Half-Year 2020 Financial Results reporting* July 23, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

Half Year 2019 Financial Results

Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.

Half Year 2019 Financial Results

Full Year 2018 Financial Results

Idorsia published its full year financial results 2018 on Thursday February 7, 2019.

 

Full Year 2018 Financial Results

Half Year 2018 Financial Results

Idorsia published its half year financial results 2018 on Tuesday July 24, 2018.

 

Half Year 2018 Financial Results

Phase 3 initiation: Aprocitentan for resistant hypertension management

In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

 

Phase 3 initiation: Aprocitentan for resistant hypertension management

Phase 3 Advancing: Clazosentan for cerebral vasospasm

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

 

Phase 3 Advancing: Clazosentan for cerebral vasospasm

Phase 3 initiation: Daridorexant for insomnia

In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of daridorexant (recommended INN for ACT-541468), a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia. NB: The proposed INN "nemorexant" was unsuccessful and will no longer be used in association with ACT-541468.

 

Phase 3 initiation: Daridorexant for insomnia

Phase 3 initiation: Lucerastat for Fabry disease

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

 

Phase 3 initiation: Lucerastat for Fabry disease

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.